InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss
MT Newswires Live
Yesterday
InnoCare Pharma (SHA:688428, HKG:9969) recorded an attributable loss of 34.3 million yuan in the third quarter of 2025, a Thursday Hong Kong bourse filing said.
Loss per share for the three months stood at 0.02 yuan, with operating revenue rising 38% to 383.9 million yuan.
The higher revenue was due to an increase in the sales revenue of core product orelabrutinib, as well as the upfront payment under an exclusive license agreement with Prolium Bioscience.
For the nine months ended Sept. 30, attributable loss reached 64.4 million yuan, while operating revenue surged 60% to 1.12 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.